About Low affinity immunoglobulin gamma Fc region receptor II-b
Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B) is a protein
from Homo sapiens identified by UniProt accession
P31994, 310 residues long.
MolForge cross-references it against 0 known binders and
828 disease associations.
Target properties
| Protein name | Low affinity immunoglobulin gamma Fc region receptor II-b |
| UniProt accession | P31994 |
| Gene | FCGR2B |
| Organism | Homo sapiens |
| Length | 310 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (828)
Diseases linked to this target (Open Targets).
- systemic lupus erythematosus · score 0.40
- total blood protein measurement · score 0.40
- blood protein measurement · score 0.38
- hemoglobin measurement · score 0.38
- head and neck squamous cell carcinoma · score 0.37
- thyroid carcinoma · score 0.37
- breast ductal adenocarcinoma · score 0.37
- birth weight · score 0.36
- low affinity immunoglobulin gamma Fc region receptor II-a/b measurement · score 0.34
- neutrophil count · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31994-F1 | alphafold | PREDICTED | 78.44 | — |
Amino-acid sequence (310 residues)
MGILSFLPVL ATESDWADCK SPQPWGHMLL WTAVLFLAPV AGTPAAPPKA VLKLEPQWIN VLQEDSVTLT CRGTHSPESD SIQWFHNGNL IPTHTQPSYR FKANNNDSGE YTCQTGQTSL SDPVHLTVLS EWLVLQTPHL EFQEGETIVL RCHSWKDKPL VKVTFFQNGK SKKFSRSDPN FSIPQANHSH SGDYHCTGNI GYTLYSSKPV TITVQAPSSS PMGIIVAVVT GIAVAAIVAA VVALIYCRKK RISALPGYPE CREMGETLPE KPANPTNPDE ADKVGAENTI TYSLLMHPDA LEEPDDQNRI
Explore Low affinity immunoglobulin gamma Fc region receptor II-b with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets